RESULTS	Concomitant topiramate resulted in decreased systemic exposure to pioglitazone and its active metabolites , with geometric LSM ratios and 90 % CI for AUC24 of 85.0 % ( 75.7 % , 95.6 % ) for pioglitazone , 40.5 % ( 36.8 % , 44.6 % ) for M-III , and 83.8 % ( 76.1 % , 91.2 % ) for M-IV , respectively .\